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Physiological changes during pregnancy may alter drug pharmacokinetics. Therefore, mechanistic understanding of these changes and,
ultimately, clinical studies in pregnant women are necessary to determine if and how dosing regimens should be adjusted. Because of
the typically limited number of patients who can be recruited in this patient group, efficient design and analysis of these studies is of
special relevance. This paper is a summary of a conference session organized at the American Conference of Pharmacometrics in April
2011, around the topic of applying pharmacometric methodology to this important problem. The discussion included both design and
analysis of clinical studies during pregnancy and in silico predictions. An overview of different pharmacometric methods relevant to this
subject was given. The impact of pharmacometrics was illustrated using a range of case examples of studies around pregnancy.
Introduction
The American Conference on Pharmacometrics (ACoP)
held its third meeting in April 2011 and included a confer-
ence session on ‘Pharmacometrics in Pregnancy:Quantify-
ing Maternal/Fetal Pharmacology’. This manuscript,
prepared by the organizers and presenters of that session,
summarizes the discussion on the application of pharma-
cometric methodologies in efficient design and analysis of
studies in order ultimately to optimize drug therapy during
pregnancy. For further details, presentation materials are
available in electronic form on the conference’s website,
http://www.go-acop.org.
Need for clinical studies in pregnant women
Pregnant women have long been orphaned from drug
studies, yet need drug treatment. Drug use during preg-
nancy can be required for either pregnancy-related or
unrelated conditions. Examples of pregnancy-related con-
ditions that require treatment are hypercoagulability, ges-
tational diabetes and pre-eclampsia. Moreover, a wide
range of conditions unrelated to pregnancy, such as either
chronic conditions including epilepsy, depression, asthma,
hypertension,diabetes andHIV,or acute conditions such as
infections (e.g. bronchitis, herpes,malaria) and cancer may
occur during pregnancy. As a consequence, drug use
during pregnancy is common. One recent study reported
that drugs were prescribed during 64% of all deliveries [1].
Ethical objections for conducting clinical studies in
pregnant women may exist, given the risk of potentially
harmful fetal exposure, as was seen in the past with thali-
domide and diethylstilbestrol [2]. However, continued off-
label treatment with drugs during pregnancy may also be
considered unethical [3], as it may be done in the absence
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of well-controlled clinical studies that can ascertain effi-
cacy and safety. This dilemma could be compared with the
historical hesitation of conducting clinical studies in the
paediatric population, which was addressed through a
concerted effort, and led to the Paediatric Rule.
Physiological changes during pregnancy
During pregnancy, pharmacokinetics may be altered due
to changes in physiology. For instance, during pregnancy,
renal function (in terms of glomerular filtration rate and
renal tubular activity) is increasing, leading to increased
clearance for renally eliminated drugs. Also, the apparent
activities of a number of cytochrome P450 and UGT drug
metabolizing enzymes are increased. Increased plasma
volume and low albumin concentrations may impact on
the volume of distribution and in some cases total drug
clearance. Depending on the physicochemical properties
of a drug, such changes may substantially impact on the
pharmacokinetics (PK) [4]. In principle, this may lead to
either medication under- or over-dosing,with varying con-
sequences for safety and efficacy. The coupled maternal-
fetal physiology imposes unique concerns for both efficacy
and safety of drug treatment [5]. In summary, for clinicians,
substantial uncertainty exists regarding the risks for fetal
and maternal exposure and the need for individually
adjusted dosing regimens during pregnancy.
Pharmacometrics and pregnancy
In principle, pharmacometric approaches may be applied
both in silico and in vivo. Model-based, analytical model-
ling and simulation approaches can be used to quantify
the effects of pregnancy in clinical studies and mechanis-
tically relatemeasured exposure to clinical response.More-
over, computer simulation of in silico pregnant subjects
can integrate mechanistic data from several sources, thus
maximizing the available information for use in designing
therapies for mother, placenta and/or fetus. The ACoP
session highlighted the state of the art and current needs
in design and analysis of pharmacokinetic studies in preg-
nant women by (i) addressing the clinical implications and
challenges of maternal-fetal pharmacology, (ii) illustrating
how pharmacometric approaches can improve the effi-
ciency of clinical study data analysis and (iii) demonstrat-
ing how applications of physiologically-based PK models
can be used to predict maternal-fetal exposure.
In this brief review we will first provide an overview of
different pharmacometric tools available for design and
analysis of clinical studies during pregnancy. Then, case
examples,which were presented during the session will be
used to illustrate where pharmacometric methods may
provide useful information. Finally, challenges and oppor-
tunities for conduct of studies in pregnant women and
associated use of pharmacometric technologies will be
discussed.
Pharmacometric tools
The pharmacometrics discipline applies a collection of
interdisciplinary quantitative tools and methodologies in
three main functional areas broadly defined as pharmaco-
kinetics, pharmacodynamics (PD) and disease modelling
(DM). Conceptually, a mechanistic description of drug
pharmacokinetics can be coupled to the signalling elicit-
ing a pharmacodynamic effect or response,which then can
be modelled accounting for the context of the temporal
physiological changes occurring during pregnancy.
In this review, we focus on the pharmacometric tools
that support PK analysis, the kind of pharmacometric
analysis most widely applied to the special population of
pregnant women. These tools include non-compartmental
analysis (NCA), compartmental individual PK analysis (IPK)
and population level PK analysis (PPK), clinical trial simula-
tion (CTS) and optimal design (OD). We also will address
physiologically based pharmacokinetic (PBPK) modelling,
which is an extension of compartmental modelling. Each
of these methods is described below. The role of these
tools in study design and analysis, is illustrated in Figure 1.
Non-compartmental analysis
Non-compartmental analysis [6] is a data drivenmethod of
analysis that requires densely sampled PK data in order to
calculate empirically integral measures (moments) such as
the area under the concentration–time curve (AUC).These
can then be used to obtain estimates for valuable PK
parameters such as mean residence time (MRT) and clear-
ance (CL). Other informative non-compartmental param-
eters include the peak concentration (Cmax) and the time at
which the peak concentration occurs (tmax). NCA based
methods work well if data are dense and with enough
resolution to estimate the above parameters reliably.
Moreover, few prior assumptions are used in calculation of
PK parameters, for example the well-known ‘equivalent
source–equivalent sink’ assumption [7]. These assumptions
need to be carefully understood to evaluate the appropri-
ate domain of validity for the non-compartmental model.
Compartmental PK analysis
Drug concentration–time profiles may also be described
using compartmental models, which allow the simulta-
neous estimation of mechanistic or semi-mechanistic PK
parameters using least squares or maximum likelihood
procedures. These models are based on (linear or non-
linear) differential equations and balance of mass prin-
ciples [8].
Compartmental or, more in general, differential
equation-based PKmodels may either be describing PK on
an individual level or on a population level. Individual level
PK analyses require relatively dense data for each subject,
whereas population level PK models allow simultaneous
estimation of mean population PK parameters, as well as
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between subject variability (of biological origin) and
residual unexplained variability (including other stochastic
factors, e.g. assay variation) [9]. Population level PK models
also allow the incorporation of covariates to understand
the influence of physiological factors on PK parameters
(e.g. estimated gestational age). Unlike NCA approaches,
PPK models are able to handle heterogeneous and
sparsely sampled data, and may therefore be especially
suitable to analyze data from clinical studies such as in
pregnancy where data often may have a sparse character.
Experiments may also be designed optimally to maximize
the probability to achieve useful information from the
data, as we will mention below.
Once a PPK model has been developed and informed
from prior knowledge or data, stochastic simulation
approaches may be used to answer questions related to
the need and the magnitude of potential dosing adjust-
ments during different periods of pregnancy.
Physiologically-based PK modelling
PBPK models are multi-compartmental models that aim to
describe mechanistically major tissues and organs in an
organism, in order to predict and quantify PK characteris-
tics of a drug. They may be used for predictive purposes
or to support study design. PBPK model predictions are
based on the physiological characteristics of drugs and
Clinical study
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Overview of pharmacometrics approaches in design and analysis of clinical studies in pregnant women
J. G .C. van Hasselt et al.
934 / 74:6 / Br J Clin Pharmacol
tissues, and on the intrinsic physicochemical drug proper-
ties. PBPK models are generally not driven by clinical data,
such as in NCA or PPK models. Because PBPK models have
a mechanistic character, they are considered most suitable
for producing extrapolations to new populations. PBPK
models are intensely studied and used in drug develop-
ment and in the study of environmental toxin exposures.
A review by Corley et al. [10] described the general PBPK
model structures which have been reported to describe
the physiological changes during pregnancy. These
models have been utilized predominantly to explore dis-
position of environmental chemicals in humans and across
various species. These previously reported model struc-
tures do have some recognized limitations, for example
they typically have not considered changes in drug
metabolizing or transporting proteins. More recently,
PBPK models were also developed specifically for selected
compounds, such as for midazolam [11] and caffeine [12].
Because of their complexity PBPK models require rich
supporting experimental data and/or make use of in silico
prediction tools to obtain required physiochemical param-
eters. Since drug-specific supporting data to informmodel
parameters and structure may not always be available,
assumptions are oftenmade based on general knowledge.
Thus it is important to verify or validate model predictions
with available data, and also to assess the sensitivity of
model predictions to key parameters in the model.
Reported PBPK models therefore have recognized limita-
tions. For example the models summarized by Corley
et al. [10] typically did not consider changes in drug
metabolizing or transporting proteins. The midazolam
model developed by Andrew et al. included changes in
metabolism based on awealth ofmetabolic data and time-
dependent physiological changes due to gestation.
However, many assumptions were made to incorporate a
detailed fetal structure. Sensitivity analysis was used to
assess how these and othermodel parameters affected the
model output [13].
Clinical trial simulation
Clinical trial simulation (CTS) [14] uses Monte Carlo sam-
pling methods to identify trial designs that are most likely
to achieve trial goals. At a minimum, a clinical trial simula-
tion may consist of an input-output model and a trial
execution model. The input-output model concerns the
stochastic simulation of pharmacokinetic profiles based
on a prior or assumed PPK model, and a dosing schedule.
The trial execution model concerns other random events
such as dropout rate, or other events related to trial execu-
tion, which may have an impact on the trial outcome. Using
CTS, different trial designs may be explored to determine
which is most likely to meet the objectives of the study.
Optimal design
OD [15] is a statistical methodology that aims to optimize
the design of a trial with respect to a design criterion, e.g.
PK parameter precision. ODs may be identified based on
prior information, which is typically a compartmental PK
model. Moreover, design characteristics and design
optimization boundaries need to be defined, e.g. the
number of subjects, number of groups, sampling time
boundaries or dose levels. An important advantage of OD
is they are often less computationally intensive, and opti-
mization is not bound to a priori defined designs such as
for CTS. Additionally, ODs can be defined on either an
individual or a population level.
Case examples
Gestational diabetes
One clinical area in which pharmacometric techniques,
including PK–PD modelling, have been applied is in the
investigation of the commonly used oral hypoglycaemic
agent, glyburide, in the treatment of women with gesta-
tional diabetes mellitus. Glyburide is a substrate for
CYP2C9, CYP3A and CYP2C19 in vitro [16, 17]. The activ-
ities of both CYP2C9 and CYP3A appear to be markedly
increased during pregnancy, in contrast to CYP2C19 activ-
ity, which appears to be decreased during pregnancy
[18–20]. Mary Hebert’s presentation at the ACoP session
described how a study run by the Obstetric-fetal pharma-
cology Research Unit Network showed that the dose-
normalized glyburide AUC was approximately 50% lower
during pregnancy than in the non-pregnant control sub-
jects.Utilizing PPKmodel based stochastic simulations, the
maximum dosage would need to be more than doubled
[21], in order to obtain the same concentrations during
pregnancy aswere observed in the non-pregnant subjects.
The clinical situation requires additional considerations
beyond observed or expected changes in maternal PK. For
example fetal and neonatal safety must be taken into con-
sideration because the safety of higher dosages has not
been evaluated during pregnancy and glyburide does
cross the placenta [21]. Another consideration is the
impact of pregnancy on the PD response to glyburide
during pregnancy. The physiologic changes that occur
even during normal pregnancy lead to a state of insulin
resistance and hyperinsulinaemia [21]. These changes
likely result in alterations in response to glyburide and
perhaps in the PK–PD relationship, and should be further
investigated. This is of course a general consideration.
Antibiotics
Another published pharmacometric application presented
by Mary Hebert was to evaluate amoxicillin prophylaxis for
Bacillus anthracis exposure. The antibiotic amoxicillin has
been recommended by the American Academy of Obstet-
rics and Gynecology for pregnant women who have been
exposed to anthrax, once penicillin-sensitivity has been
confirmed [22]. However, amoxicillin is primarily eliminated
unchanged in the urine and pregnancy is known to
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increase renal filtration, with creatinine clearance increas-
ing to 150–160% of non-pregnant values [23–27]. In a
small study of amoxicillin exposure, NCA PK evaluation of
amoxicillin, single dose (500 mg orally) has demonstrated
that amoxicillin AUC is significantly lower in both the
second and third trimesters of pregnancy than in the same
women 3months post partum. In addition, the average
half-life during pregnancy was 1.2 h in the second trimes-
ter and 1.3 h in the third trimester, compared with 1.6 h
3 months post partum, raising concerns about the recom-
mended dosage of amoxicillin for both pregnant on non-
pregnant individuals.
PPK modelling and simulation allowed investigation of
optimized dosing regimens. Based on these analyses,
amoxicillin would need to be dosed every 4 h to keep
amoxicillin trough concentrations above 0.12 mgml-1,
which is the minimum inhibitory concentration for sensi-
tive B. anthracis isolates. These simulations suggest that,
given the prolonged course of 60 days needed in the
setting of anthrax exposure prophylaxis, an every 4 h
dosing regimen would be particularly challenging if not
impossible to implement [28].
Anti-malarial drugs
Malaria is one of the most important infectious diseases in
the world and affects the population of many of the
poorest countries. Pregnant women are especially vulner-
able to malaria, with an estimated 85 million pregnancies
occurring in areas with P. falciparum transmission during
2007 [29]. The physiological changes during pregnancy
also tend to result in altered PK properties of many of the
anti-malarials used today. In Joel Tarning’s presentation, it
was shown how previous studies reported that artesunate,
artemether, dihydroartemisinin, sulfadoxine, atovaquone,
progunanil, cycloguanil, pyrimethamine and lumefantrine
concentrations and cure rates were lower in pregnant
women compared with non-pregnant adults [20, 30–34].
A meta-analysis by McGready et al. [35] showed that nine
out of 12 included PK studies recommended dose optimi-
zation in pregnant women with malaria. Unacceptably
high polymerase chain reaction (PCR)-corrected failure
rates of 16.5% (95% CI 9.9, 25.1) after artemether-
lumefantrine treatment (Coartem®) in pregnant women
with malaria in Thailand [33] have been reported.
Joel Tarning illustrated how PPK modelling of lumefan-
trine was used to quantify altered PK parameters during
pregnancy, which resulted in low drug concentrations in
the terminal phase. Results of stochastic simulations using
the developed PPK model suggested that this combina-
tion treatment needs to be administered for an extended
period of time in pregnant women, in order to kill residual
parasites efficiently. The lower drug concentrations of
lumefantrine in the terminal phase are likely to explain the
high recrudescence (regrowth of the same parasite) rate
seen in pregnant women and emphasize the need for dose
optimization in this especially vulnerable group.
Finally, given the challenging conditions in the often
remote areas where the studies of anti-malarials in the
pregnant population are performed, Joel Tarning sug-
gested that the use of informative sparse sampling designs
is highly relevant for the conduct of PK studies in this par-
ticular area. Jamsen et al. [36] described this approach for
anti-malarial studies.
Influenza drugs
Pregnant women who contract influenza face a signifi-
cantly increased risk for admission to hospital and associ-
ated morbidity and mortality [37]. Identifying more
effective influenza therapies or regimens during preg-
nancy is of special interest. While oseltamivir is recom-
mended for use during pregnancy, until recently no data
were available regarding its disposition during pregnancy.
Consequently, it was not known whether the recom-
mended adult prophylaxis and treatment dosages were
adequate.
Oseltamivir is a pro-drug, metabolized by carboxy-
lesterases in the gut and liver to the active drug oseltamivir
carboxylate. Simple approximations for changes in dispo-
sition during pregnancy for both oseltamivir and oselta-
mivir carboxylate were predicted using compartmental
approaches, as described in Donald Mattison’s presenta-
tion. This was done using available adult drug disposition
data [38–52], in which model clearances were modified
based on the knowledge of physiological changes during
pregnancy. Glomerular filtration rate increases about 50%,
renal plasma flow increases about 70% and extracellular
fluid volume increases about 30–40% by the third trimes-
ter of pregnancy. Drug disposition could then be predicted
in pregnant women. The volume of distribution was pre-
dicted to change from 120 to 170 l and the apparent clear-
ancewas predicted to change from 27 to 41 l h-1. Using the
estimated changes in maternal physiological parameters,
exposure during pregnancy could be compared with that
in non-pregnant adults. Overall, these results predicted
that the AUC was reduced by 30% in pregnancy compared
with the non pregnant individual. Subsequently, these
simulated observations were validated using recent clini-
cal data from a small study of oseltamivir and oseltamivir
carboxylate PK during pregnancy [53–55], illustrating the
utility of quantitative approaches to the evaluation of clini-
cal therapeutics during pregnancy.
Challenges and opportunities
Design and conduct of an ethical yet informative study in
this special population can be challenging. Capturing
changes in PK during pregnancy may be complicated due
to practical difficulties such as limited recruitment of sub-
jects, limited numbers of feasible blood samples or sam-
pling occasions. When designing and analyzing a clinical
study, ideally pregnancy should not be treated as a
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dichotomous covariate, since changes in physiological
parameters and PK are continuous. Moreover, the combi-
nation of small sample sizes and large inter- and
intra-patient variability in PK parameters may further com-
plicate the detection of significant changes in PK param-
eters during pregnancy.
As illustrated in the case examples covered during the
ACoP session, pharmacometric approaches such as
optimal design [56] or simulation studies may be used to
support design of informative studies in this vulnerable
population in various ways. These include sparse sampl-
ing designs, leveraging of physiological data to quantify
anticipated changes in PK, conducting the trial in silico
before its execution in vivo, and the overall evaluation of
potential study designs for their likelihood of quantifying
the (changes in) PK parameters of interest. All these
approaches generate information or hypotheses that can
be rigorously tested as data become available from con-
trolled experiments. As clinical studies have been per-
formed,these datamay also be used to evaluate or validate
the performance of developed models and further
improve these models based on observed data.
Relevant methods available for analyzing PK studies
were briefly discussed, each with their own benefits and
drawbacks. It is important to consider carefully an appro-
priate method, or combination of methods, specific to the
question to be answered. Semi-physiological approaches
may sometimes be considered, offering benefits of both
PPK and PBPK methods. Further advances in PBPK models
are expected to be useful in further exploration of both
maternal and fetal exposure in silico. Increased under-
standing of maternal-fetal transport processes and
gestationally-induced changes in drug metabolism and
transport would be especially helpful in improving the
utility of PBPK models.
Optimizing drug treatment in (pregnant) patients is
related ultimately to observed variability within and
between patients, both in PK and PD. Such variations are
the sum of the interplay between difference in physiological
changes during pregnancy and other causes such as differ-
ences in metabolism (e.g. pharmacogenetic variation),
patient compliance or obesity. The multitude of factors
influencing PK and PD complicates the assessment of
changes in the pharmacology of drugs during pregnancy.
The session and this review focused on changes in PK in
the pregnant women. Post partum changes inmaternal PK
were not specifically discussed, but should ideally also be
investigated in any clinical study aiming to investigate
changes in PK during pregnancy, as it is not expected that
PK will change back to the non-pregnant baseline instan-
taneously. Another subject which was discussed in this
review was assessment of fetal exposure through the pla-
centa and drug exposure through breast milk. However, as
indicated, PBPK methods would be expected to be the
most appropriate methodology to provide quantitative
predictions for these events.
We discussed the specific challenges related to the
design, conduct and analysis of clinical studies in pregnant
women, underlining the unmet need for pharmacometric
analysis approaches and examples of impact to date.
There have been significant developments in pharmaco-
metric models over the past three decades, as well as
increased understanding of the profound physiological
changes which occur during pregnancy. The pharmaco-
metric approaches discussed allow design and analysis of
more informative studies. However, effective application
of pharmacometric methods is dependent on interdiscipli-
nary expertise and collaboration, in order ultimately to
support the improvement in care for pregnant women and
their offspring.
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